WO2005023778A3 - Process for preparation of rosuvastatin calcium - Google Patents
Process for preparation of rosuvastatin calcium Download PDFInfo
- Publication number
- WO2005023778A3 WO2005023778A3 PCT/US2004/027530 US2004027530W WO2005023778A3 WO 2005023778 A3 WO2005023778 A3 WO 2005023778A3 US 2004027530 W US2004027530 W US 2004027530W WO 2005023778 A3 WO2005023778 A3 WO 2005023778A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rosuvastatin calcium
- preparation
- impurities
- substantially free
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04782093A EP1562912A2 (en) | 2003-08-28 | 2004-08-24 | Process for preparation of rosuvastatin calcium |
CA002537271A CA2537271A1 (en) | 2003-08-28 | 2004-08-24 | Process for preparation of rosuvastatin calcium |
IL173858A IL173858A0 (en) | 2003-08-28 | 2006-02-21 | Process for preparation of rosuvastatin calcium |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49876403P | 2003-08-28 | 2003-08-28 | |
US60/498,764 | 2003-08-28 | ||
US53467804P | 2004-01-06 | 2004-01-06 | |
US60/534,678 | 2004-01-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005023778A2 WO2005023778A2 (en) | 2005-03-17 |
WO2005023778A3 true WO2005023778A3 (en) | 2005-06-16 |
Family
ID=34278611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/027530 WO2005023778A2 (en) | 2003-08-28 | 2004-08-24 | Process for preparation of rosuvastatin calcium |
Country Status (6)
Country | Link |
---|---|
US (1) | US7396927B2 (en) |
EP (1) | EP1562912A2 (en) |
CA (2) | CA2657076A1 (en) |
IL (1) | IL173858A0 (en) |
TW (2) | TW200518756A (en) |
WO (1) | WO2005023778A2 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
CA2657076A1 (en) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin calcium |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
CA2546701C (en) * | 2003-11-24 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
US7851624B2 (en) | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
US20070179166A1 (en) * | 2003-12-24 | 2007-08-02 | Valerie Niddam-Hildesheim | Process for preparation of statins with high syn to anti ratio |
CA2576196A1 (en) | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
TWI353981B (en) * | 2005-02-22 | 2011-12-11 | Teva Pharma | Preparation of rosuvastatin |
SI1915349T1 (en) | 2005-06-24 | 2016-05-31 | Lek Pharmaceuticals D.D. | Process for preparing pure amorphous rosuvastatin calcium |
JP5146965B2 (en) * | 2005-06-24 | 2013-02-20 | レツク・フアーマシユーテイカルズ・デー・デー | Method for preparing amorphous rosuvastatin calcium free of impurities |
CZ299215B6 (en) * | 2005-06-29 | 2008-05-21 | Zentiva, A. S. | Process for preparing hemi-calcium salt of rosuvastatin, i.e. (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid |
US20070099994A1 (en) * | 2005-08-16 | 2007-05-03 | Valerie Niddam-Hildesheim | Rosuvastatin calcium with a low salt content |
US7868169B2 (en) | 2005-08-16 | 2011-01-11 | Teva Pharmaceutical Industries, Ltd. | Crystalline rosuvastatin intermediate |
KR20090113920A (en) * | 2005-10-03 | 2009-11-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | Diastereomeric purification of rosuvastatin |
US7351853B2 (en) * | 2006-01-23 | 2008-04-01 | Albion Advanced Nutrition | Method of manufacturing a granular mineral composition |
WO2007099561A1 (en) * | 2006-02-27 | 2007-09-07 | Cadila Healthcare Limited | Process for preparing rosuvastatin calcium |
WO2007125547A2 (en) * | 2006-05-03 | 2007-11-08 | Manne Satyanarayana Reddy | Novel process for statins and its pharmaceutically acceptable salts thereof |
EP1948618A1 (en) * | 2006-09-18 | 2008-07-30 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin calcium |
HUE028475T2 (en) | 2006-10-09 | 2016-12-28 | Msn Laboratories Private Ltd | Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof |
WO2008053334A2 (en) * | 2006-10-31 | 2008-05-08 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin calcium |
EP2125754B1 (en) * | 2007-02-08 | 2012-04-11 | Aurobindo Pharma Limited | Process for preparation of rosuvastatin calcium |
EP2178890A1 (en) * | 2007-07-12 | 2010-04-28 | Teva Pharmaceutical Industries Ltd. | Purification of rosuvastatin intermediate by thin film evaporation and chemical method |
WO2009143776A1 (en) | 2008-05-27 | 2009-12-03 | 常州制药厂有限公司 | Preparation method of rosuvastatin calcium and its intermediates |
CN102317267A (en) * | 2009-01-15 | 2012-01-11 | 埃吉斯药物股份公开有限公司 | Process for the preparation of rosuvastatin salts |
US8487105B2 (en) | 2009-01-19 | 2013-07-16 | Msn Laboratories Limited | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof |
US8987444B2 (en) | 2010-01-18 | 2015-03-24 | Msn Laboratories Private Limited | Process for the preparation of amide intermediates and their use thereof |
HU230987B1 (en) | 2010-11-29 | 2019-08-28 | Egis Gyógyszergyár Nyrt. | Process for the preparation of pharmaceutical intermediates with high purity |
WO2012143308A1 (en) | 2011-04-18 | 2012-10-26 | Basf Se | Multicomponent crystalline system of rosuvastatin calcium salt and vanillin |
MX368148B (en) * | 2013-03-14 | 2019-09-20 | Boryung Pharm | Pharmaceutical combination drug. |
US9850213B2 (en) * | 2013-11-25 | 2017-12-26 | Jiangxi Boya Seehot Pharmaceutical Co., Ltd. | Method for preparing rosuvastatin sodium |
CN104788387A (en) * | 2015-04-17 | 2015-07-22 | 浙江海森药业有限公司 | Preparation method for high-purity rosuvastatin calcium |
CN109580789B (en) * | 2017-09-28 | 2021-06-22 | 安徽省庆云医药股份有限公司 | Method for separating and measuring rosuvastatin tert-butyl ester and optical isomer thereof by liquid chromatography |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003016317A1 (en) * | 2001-08-16 | 2003-02-27 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
WO2003097614A2 (en) * | 2002-05-21 | 2003-11-27 | Ranbaxy Laboratories Limited | Process for the preparation of rosuvastatin |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (en) * | 1980-06-06 | 1987-04-10 | Sankyo Co | A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B |
US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
NO177005C (en) * | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogous process for the preparation of substituted pyridines, as well as intermediates for use in the preparation |
US5177080A (en) * | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP3233403B2 (en) * | 1991-06-19 | 2001-11-26 | 塩野義製薬株式会社 | Optically active intermediate and method for producing the same |
JP2648897B2 (en) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | Pyrimidine derivatives |
US6063633A (en) * | 1996-02-28 | 2000-05-16 | The University Of Houston | Catalyst testing process and apparatus |
GB9626746D0 (en) | 1996-12-23 | 1997-02-12 | Knoll Ag | Process |
GB9812413D0 (en) | 1998-06-10 | 1998-08-05 | Glaxo Group Ltd | Compound and its use |
SI20070A (en) | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | NOVEL SALTS OF INHIBITORS OF HMG-CoA REDUCTASE |
GB9903472D0 (en) | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
US6777552B2 (en) * | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
GB0028429D0 (en) * | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
SE0103509D0 (en) | 2001-10-19 | 2001-10-19 | Astrazeneca Ab | Rosuvastatin in pre-demented states |
KR100511533B1 (en) | 2002-04-09 | 2005-08-31 | 임광민 | CHIRAL INTERMEDIATE, PROCESS FOR THE PRODUCTION THEREOF, AND PROCESS FOR THE PRODUCTION OF HMG-CoA REDUCTASE INHIBITOR |
GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
HUP0500851A3 (en) | 2002-12-10 | 2008-02-28 | Ranbaxy Lab Ltd | Process for the preparation of rosuvastatin |
WO2005021511A1 (en) | 2003-08-27 | 2005-03-10 | Hetero Drugs Limited | A novel process for amorphous rosuvastatin calcium |
CA2657076A1 (en) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin calcium |
CA2546701C (en) * | 2003-11-24 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
EP1797046A2 (en) | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
CA2594692A1 (en) | 2005-01-31 | 2006-08-03 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of rosuvastatin calcium salt |
EP1863773A1 (en) | 2005-03-22 | 2007-12-12 | Unichem Laboratories Limited | Process for preparation of rosuvastatin |
EP1869005A1 (en) | 2005-04-04 | 2007-12-26 | Unichem Laboratories Limited | Process for preparation of calcium salt of rosuvastatin |
SI1915349T1 (en) | 2005-06-24 | 2016-05-31 | Lek Pharmaceuticals D.D. | Process for preparing pure amorphous rosuvastatin calcium |
JP5146965B2 (en) | 2005-06-24 | 2013-02-20 | レツク・フアーマシユーテイカルズ・デー・デー | Method for preparing amorphous rosuvastatin calcium free of impurities |
GB0514078D0 (en) | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
-
2004
- 2004-08-24 CA CA002657076A patent/CA2657076A1/en not_active Abandoned
- 2004-08-24 CA CA002537271A patent/CA2537271A1/en not_active Abandoned
- 2004-08-24 EP EP04782093A patent/EP1562912A2/en not_active Withdrawn
- 2004-08-24 US US10/925,430 patent/US7396927B2/en not_active Expired - Fee Related
- 2004-08-24 WO PCT/US2004/027530 patent/WO2005023778A2/en active Application Filing
- 2004-08-27 TW TW093125904A patent/TW200518756A/en unknown
- 2004-08-27 TW TW097151496A patent/TW200920374A/en unknown
-
2006
- 2006-02-21 IL IL173858A patent/IL173858A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003016317A1 (en) * | 2001-08-16 | 2003-02-27 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
WO2003097614A2 (en) * | 2002-05-21 | 2003-11-27 | Ranbaxy Laboratories Limited | Process for the preparation of rosuvastatin |
Non-Patent Citations (1)
Title |
---|
WATANABE M ET AL: "SYNTHESIS AND BIOLOGICAL ANTIVITY OF METHANESULFONAMIDE PYRIMIDINE-AND N-METHANESULFONYL PYRROLE-SUBSTITUTED 3,5-DIHYDROXY-6-HEPTENOATES, A NOVEL SERIES OF HMG-COA REDUCTASE INHIBITORS", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 5, no. 2, 1997, pages 437 - 444, XP000882043, ISSN: 0968-0896 * |
Also Published As
Publication number | Publication date |
---|---|
TW200518756A (en) | 2005-06-16 |
IL173858A0 (en) | 2006-07-05 |
TW200920374A (en) | 2009-05-16 |
EP1562912A2 (en) | 2005-08-17 |
WO2005023778A2 (en) | 2005-03-17 |
CA2657076A1 (en) | 2005-03-17 |
US7396927B2 (en) | 2008-07-08 |
CA2537271A1 (en) | 2005-03-17 |
US20050080134A1 (en) | 2005-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005023778A3 (en) | Process for preparation of rosuvastatin calcium | |
TW200508201A (en) | Novel process for the preparation of roflumilast | |
TW200611692A (en) | Processes for preparation of crystalline mycophenolate sodium | |
WO2003106416A3 (en) | Chemical process | |
WO2006110783A3 (en) | Process for making (s)-pregabalin | |
IL160077A0 (en) | Processes for preparing calcium salt forms of statins | |
WO2004074244A3 (en) | Pyrimidine compounds | |
WO2006091770A3 (en) | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof | |
IL166626A0 (en) | Process for preparing the calcium salt of rosuvastatin | |
WO2004047879A3 (en) | Antimicrobial lenses, processes to prepare them and methods of their use | |
PL371127A1 (en) | 6-aminomorphinane derivatives, method for the production and use thereof | |
PT1509517E (en) | Novel synthesis of irbesartan | |
TWI349008B (en) | Ionic liquids having fluoroalkyltrifluoroborate anions | |
AU2002235326A1 (en) | Processes for large scale production of tetrapyrroles | |
WO2005063708A3 (en) | Processes for preparing different forms of (s)-(+)- clopidogrel bisulfate | |
ZA200602149B (en) | Process for the synthesis of 6-amino-4-[(3-chloro-4-fluo-rophenyl)amino]-7-ethoxy-quinoline-3-carbonitrile | |
WO2004048380A8 (en) | Process for the synthesis of ganciclovir | |
AU2002367268A1 (en) | Processes for production of cyclic diamine compounds or salts thereof | |
WO2006122020A3 (en) | Process for production of 4-biphenylyazetidin-2-ones | |
WO2004075860A3 (en) | Process for purification of zoledronic acid | |
WO2004089863A8 (en) | Process for the production of 2-hydroxy-4-methylthiobutyric acid ammonium salt | |
TW200510323A (en) | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | |
WO2006027658A3 (en) | Process for the preparation of sertraline hydrochloride form ii | |
MXNL04000051A (en) | Process for the production of an immunosuppressant. | |
TW200732342A (en) | Process for the preparation of purified crystalline CCI-779 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480024487.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004782093 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2004782093 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 658/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 173858 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2537271 Country of ref document: CA |